J&J, states settle on Risperdal

As part of a $181-million settlement with states to resolve charges of improper marketing and advertising, Johnson & Johnson agreed to stop several practices regarding Ripserdal and its cousin Invega.

Marc Iskowitz

October 1, 2012

4:00 am

As part of a $181-million settlement with states to resolve charges of improper marketing and advertising, Johnson & Johnson agreed to stop several practices regarding Ripserdal and its cousin Invega.

These include misusing CME programs for marketing; awarding grants to doctors based on prescribing habits; presenting information that is not scientifically sound; and disseminating reprints with off-label usage information.

At press time, J&J was expected to pay up to $2.2 billion for the same allegations by DOJ involving these and other drugs.

On its website, J&J said it’s not admititng any Risperdal wrongdoing.

From the October 01, 2012 Issue of MM+M - Medical Marketing and Media

From Our Partners

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.